These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 27349498)
1. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells. Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498 [TBL] [Abstract][Full Text] [Related]
2. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505 [TBL] [Abstract][Full Text] [Related]
5. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402 [TBL] [Abstract][Full Text] [Related]
6. Statin derivatives as therapeutic agents for castration-resistant prostate cancer. Ingersoll MA; Miller DR; Martinez O; Wakefield CB; Hsieh KC; Simha MV; Kao CL; Chen HT; Batra SK; Lin MF Cancer Lett; 2016 Dec; 383(1):94-105. PubMed ID: 27687622 [TBL] [Abstract][Full Text] [Related]
7. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Martin SK; Kyprianou N Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899 [TBL] [Abstract][Full Text] [Related]
8. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer. Li M; Liu M; Han W; Wang Z; Han D; Patalano S; Macoska JA; Balk SP; He HH; Corey E; Gao S; Cai C Cancer Res; 2023 May; 83(10):1684-1698. PubMed ID: 36877164 [TBL] [Abstract][Full Text] [Related]
9. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374 [TBL] [Abstract][Full Text] [Related]
10. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer. Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511 [TBL] [Abstract][Full Text] [Related]
12. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer. Tang DE; Dai Y; He JX; Lin LW; Leng QX; Geng XY; Fu DX; Jiang HW; Xu SH J Pathol; 2020 Oct; 252(2):101-113. PubMed ID: 32617978 [TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells. Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354 [TBL] [Abstract][Full Text] [Related]
14. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways. Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069 [TBL] [Abstract][Full Text] [Related]
15. Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. Handle F; Prekovic S; Helsen C; Van den Broeck T; Smeets E; Moris L; Eerlings R; Kharraz SE; Urbanucci A; Mills IG; Joniau S; Attard G; Claessens F Sci Rep; 2019 Sep; 9(1):13786. PubMed ID: 31551480 [TBL] [Abstract][Full Text] [Related]
16. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer. Pilling A; Kim SH; Hwang C Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379 [TBL] [Abstract][Full Text] [Related]
17. Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc. Hatano K; Yamaguchi S; Nimura K; Murakami K; Nagahara A; Fujita K; Uemura M; Nakai Y; Tsuchiya M; Nakayama M; Nonomura N; Kaneda Y Mol Cancer Res; 2013 Sep; 11(9):1088-100. PubMed ID: 23788635 [TBL] [Abstract][Full Text] [Related]
18. Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells. Wang Q; He WY; Zeng YZ; Hossain A; Gou X Int Urol Nephrol; 2018 Apr; 50(4):675-686. PubMed ID: 29460131 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer. Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314 [TBL] [Abstract][Full Text] [Related]